Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

ENESTop 5-Year Update: Durability of Treatment-Free Remission Following Second-Line Nilotinib and Exploratory Analysis of Molecular Response Regain after Nilotinib Re-Initiation in Patients with Chronic Myeloid Leukemia

Francois-Xavier Mahon, MD PhD, Nelma D Clementino, MD, Mikhail Fominykh, MD, Jeffrey H. Lipton, MD PhD, Anna G. Turkina, Prof., MD, Beatriz Moiraghi, MD, Franck E Nicolini, MDPhD, Naoto Takahashi, MD PhD, Tomasz Sacha, MDPhD, Dong-Wook Kim, MD, Rafik Fellague-Chebra, MD, Ranjan Tiwari, MSc, Catherine Bouard, Timothy P. Hughes, MDMBBS,FRACP,FRCPA

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-136250

Published: 2020

Journal Articles

Analyses of Predictors of Durable Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Frontline or Second-Line Nilotinib

Jerald P. Radich, MD, Andreas Hochhaus, MD, Francis J. Giles, MD FRCPI, FRCPath, David M. Ross, MD, Giuseppe Saglio, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Dong-Wook Kim, Rafik Fellague-Chebra, MD, Manu Sondhi, MD PhD, Ranjan Tiwari, MSc, Kaushal Mishra, PhD, Francois-Xavier Mahon, MD PhD

Blood (2019) 134 (Supplement_1): 2932.

https://doi.org/10.1182/blood-2019-129393

Published: 2019

Journal Articles

Impact of Treatment Cessation on Overall Disease Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Attempting Treatment-Free Remission (TFR): Findings from Enestfreedom and Enestop

Giuseppe Saglio, MD PhD, Timothy P. Hughes, MD, Andreas Hochhaus, MD, Dong-Wook Kim, MD PhD, Francis J. Giles, MD MB, FRCPath, Jerald P. Radich, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Prashanth Gopalakrishna, MD, Weiping Deng, Rafik Fellague-Chebra, MD, Sandip Acharya, MSc, Francois-Xavier Mahon, MD PhD

Blood (2017) 130 (Supplement 1): 1598.

https://doi.org/10.1182/blood.V130.Suppl_1.1598.1598

Published: 2017

Journal Articles

Treatment-Free Remission (TFR) Among Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Not Initially Eligible for Treatment Discontinuation Due to Unstable Deep Molecular Response (DMR): Enestfreedom and Enestop

Timothy P. Hughes, MD, Andreas Hochhaus, MD, Dong-Wook Kim, MD PhD, Francois-Xavier Mahon, MD PhD, Francis J. Giles, MD MB, FRCPath, Jerald P. Radich, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Prashanth Gopalakrishna, MD, Weiping Deng, Rafik Fellague-Chebra, MD, Sandip Acharya, MSc, Giuseppe Saglio, MD PhD

Blood (2017) 130 (Supplement 1): 2878.

https://doi.org/10.1182/blood.V130.Suppl_1.2878.2878

Published: 2017

Journal Articles

Efficacy and Safety of Ofatumumab and Bendamustine Followed By Ofatumumab Maintenance in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma after Prior Rituximab

Kathryn S. Kolibaba, MD, Mikhail Shtivelband, MD PhD, Edwin C. Kingsley, MD, Mehdi M. Moezi, MD, Donald Richards, MD PhD, Jeffrey P. Sharman, MD, Feng Xiaoshu, MS, Megan Cannan, B.S, Rafik Fellague-Chebra, MD, Roger M. Lyons, MD

Blood (2017) 130 (Supplement 1): 1500.

https://doi.org/10.1182/blood.V130.Suppl_1.1500.1500

Published: 2017

Journal Articles

Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop

Timothy P. Hughes, MD FRACP, FRCPA, MBBS, FAAHMS, Carla Maria Boquimpani, Naoto Takahashi, MD PhD, Noam Benyamini, MD, Nelma Cristina D Clementino, MD, Vasily Shuvaev, MD, Sikander Ailawadhi, MD, Jeffrey H. Lipton, MD PhD, Anna G Turkina, Prof., MD, Elena Beatriz Moiraghi, MD, Franck E. Nicolini, MD PhD, Jolanta Dengler, Tomasz Sacha, Dong-Wook Kim, MD PhD, Rafik Fellague-Chebra, MD MSc, Sandip Acharya, MSc, Nancy Krunic, PhD, Yu Jin, MS, François-Xavier Mahon, MD PhD

Blood (2016) 128 (22): 792.

https://doi.org/10.1182/blood.V128.22.792.792

Published: 2016

Journal Articles

Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTop Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

Blood (2016) 128 (22): 1891.

https://doi.org/10.1182/blood.V128.22.1891.1891

Published: 2016

Journal Articles

Recombinant (rec) MAGE-A3 Protein Immunotherapy and Peripheral Blood Lymphocyte (PBL) Reconstitution Induce Strong Antigen-Specific Humoral and Cellular Immune Responses in Patients Undergoing Autologous Stem Cell Transplantation (ASCT) for Consolidation of Multiple Myeloma (MM)

Adam D. Cohen, MD, Nikoletta Lendvai, MDPhD, Sacha Gnjatic, PhD, Achim A Jungbluth, MD, Stephane Bertolini, Linda Pan, Pharm.D., Ralph Venhaus, Ioanna Tsakos, Katarzyna Garcia, MS, Linda Thibodeau, RN, Katherine Alpaugh, PhD, Nailah Cummings, Rafik Fellague-Chebra, MD, Olivier Gruselle, Hearn J. Cho, MD PhD

Blood (2014) 124 (21): 1184.

https://doi.org/10.1182/blood.V124.21.1184.1184

Published: 2014

Journal Articles

MAGE-A3 Recombinant Protein (recMAGE-A3) Immunotherapy and Autologous Peripheral Blood Lymphocyte (PBL) Infusion Is Safe and Induces Robust Humoral Immune Responses In Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplantation (autoSCT)

Adam D Cohen, MD, Nikoletta Lendvai, MD PhD, Sacha Gnjatic, Ph.D., Achim A Jungbluth, MD, Stephane Bertolini, Linda Pan, Pharm.D., Ralph Venhaus, Ioanna Tsakos, Katarzyna Garcia, MS, Linda Thibodeau, RN, Katherine Alpaugh, PhD, Nailah Cummings, Rafik Fellague-Chebra, MD, Olivier Gruselle, Hearn J. Cho, MD, PhD

Blood (2013) 122 (21): 154.

https://doi.org/10.1182/blood.V122.21.154.154

Published: 2013

NARROW

ENESTop 5-Year Update: Durability of Treatment-Free Remission Following Second-Line Nilotinib and Exploratory Analysis of Molecular Response Regain after Nilotinib Re-Initiation in Patients with Chronic Myeloid Leukemia

Analyses of Predictors of Durable Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Frontline or Second-Line Nilotinib

Impact of Treatment Cessation on Overall Disease Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Attempting Treatment-Free Remission (TFR): Findings from Enestfreedom and Enestop

Treatment-Free Remission (TFR) Among Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Not Initially Eligible for Treatment Discontinuation Due to Unstable Deep Molecular Response (DMR): Enestfreedom and Enestop

Efficacy and Safety of Ofatumumab and Bendamustine Followed By Ofatumumab Maintenance in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma after Prior Rituximab

Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop

Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTop Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

Recombinant (rec) MAGE-A3 Protein Immunotherapy and Peripheral Blood Lymphocyte (PBL) Reconstitution Induce Strong Antigen-Specific Humoral and Cellular Immune Responses in Patients Undergoing Autologous Stem Cell Transplantation (ASCT) for Consolidation of Multiple Myeloma (MM)

MAGE-A3 Recombinant Protein (recMAGE-A3) Immunotherapy and Autologous Peripheral Blood Lymphocyte (PBL) Infusion Is Safe and Induces Robust Humoral Immune Responses In Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplantation (autoSCT)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only